Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI)is a novel treatment for metastatic gemcitabine-refractory pancreatic cancer. We endeavored to identify circulating markers for TAK1 activation predicting chemoresistance in this setting.
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer
Merz, Valeria;Zecchetto, Camilla;Santoro, Raffaela;Simionato, Francesca;Sabbadini, Fabio;Mangiameli, Domenico;Piro, Geny;Cavaliere, Alessandro;Valenti, Maria Teresa;Bazan, Diana;Fedele, Vita;Melisi, Davide
2020-01-01
Abstract
Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI)is a novel treatment for metastatic gemcitabine-refractory pancreatic cancer. We endeavored to identify circulating markers for TAK1 activation predicting chemoresistance in this setting.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
59).pdf
solo utenti autorizzati
Descrizione: Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Tipologia:
Versione dell'editore
Licenza:
Copyright dell'editore
Dimensione
891.54 kB
Formato
Adobe PDF
|
891.54 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
